SCYNEXIS Secures BARDA Contract of Up to $214 Million for Antifungal SCY-247

SCYNEXIS was awarded a BARDA contract providing up to approximately $214 million in non-dilutive funding, if all options are exercised, to advance development of its antifungal candidate SCY-247, including approximately $18.5 million in the initial base period. The clinical-stage biotechnology company announced the award alongside its third-quarter 2026 results, Stock Titan reported.

How the BARDA Award Is Structured

SCYNEXIS is a Jersey City-based clinical-stage biotechnology company developing the fungerp class of triterpenoid antifungal therapies, including approved BREXAFEMME, which is licensed to GSK, and the direct AMPK activator SCY-770 for autosomal dominant polycystic kidney disease. The BARDA contract is structured as a cost-share arrangement, and SCYNEXIS expects to fund its share of near-term SCY-247 program costs within its existing operating plan. The initial base period funding is intended to advance oral and intravenous SCY-247 into a Phase 2 study in invasive candidiasis. SCYNEXIS completed a Phase 1 study of intravenous SCY-247, and on October 22, 2026 announced topline results from a Phase 1 single and multiple ascending dose trial of the intravenous formulation in 56 healthy participants. IV SCY-247 was generally well tolerated, with no drug-related serious adverse events, and once-daily IV doses of 50 mg or higher achieved exposures at or above the efficacy target identified in murine models of invasive candidiasis. The company expects to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement.

SCYNEXIS's Cash Position and Pipeline Spending

According to akta.pro company records, SCYNEXIS acquired SCY-770 (PXL-770) from Poxel S.A. in March 2026 for up to $196 million, including an $8 million upfront payment and milestone payments based on clinical and commercial achievements. The same records show a $40 million private placement announced in March 2026, with potential for an additional $52.2 million, extending cash runway to mid-2029. SCYNEXIS reported cash, cash equivalents and investments of $63.2 million on September 30, 2026, compared with $71.1 million on June 30, 2026, and expects that position to support operations into 2029.

Earlier Steps Toward the SCY-247 Program

SCYNEXIS appointed Todd Minga, M.D., as Senior Vice President, Research & Development, effective September 14, 2026, Stock Titan reported; he brought more than two decades of experience in kidney disease and rare disorders, previously at Akebia Therapeutics. On October 22, 2026, The future of trading reported that SCYNEXIS secured the BARDA contract for SCY-247 development, contingent on milestones. SCYNEXIS reported second-quarter 2026 net income of $7.4 million, driven by fair value adjustments on warrant liabilities, while ending the quarter with $71.1 million in cash, Yahoo reported.

What Comes Next for SCY-770 and SCY-247

SCYNEXIS remains on track to initiate a Phase 2 proof-of-concept study of SCY-770 in ADPKD patients in the fourth quarter of 2026, with an anticipated interim analysis in the fourth quarter of 2027.